Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia.

[1]  C. Raison,et al.  C-reactive protein and response to lurasidone in patients with bipolar depression , 2018, Brain, Behavior, and Immunity.

[2]  G. Martinotti,et al.  Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review , 2018, Current neuropharmacology.

[3]  Dean P. Jones,et al.  Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study , 2018, Journal of Neuroinflammation.

[4]  J. Rybakowski,et al.  Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review , 2017, Schizophrenia Research.

[5]  M. Trivedi,et al.  Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial , 2017, Psychoneuroendocrinology.

[6]  Sunita K. Patel,et al.  Convergent and criterion validity of the CogState computerized brief battery cognitive assessment in women with and without breast cancer , 2017, The Clinical neuropsychologist.

[7]  G. Martinotti,et al.  Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice , 2016, CNS Spectrums.

[8]  M. Pourfarzam,et al.  The difference in correlation between insulin resistance index and chronic inflammation in type 2 diabetes with and without metabolic syndrome , 2016, Advanced biomedical research.

[9]  G. Martinotti,et al.  Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials , 2016, Mediators of inflammation.

[10]  M. Ikeda,et al.  A significant causal association between C-reactive protein levels and schizophrenia , 2016, Scientific Reports.

[11]  M. Schwarz,et al.  The role of inflammation in schizophrenia , 2015, Front. Neurosci..

[12]  M. Berk,et al.  C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications , 2015, Molecular Psychiatry.

[13]  P. Buckley,et al.  Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses , 2015, Brain, Behavior, and Immunity.

[14]  E. Feldman,et al.  Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome , 2015, Experimental & Molecular Medicine.

[15]  K. Tansey,et al.  An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. , 2014, The American journal of psychiatry.

[16]  S. Spencer,et al.  Named Series : Diet , Inflammation and the Brain Obesity and neuroinflammation : A pathway to cognitive impairment , 2014 .

[17]  S. Legrand-Poels,et al.  Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. , 2014, Diabetes research and clinical practice.

[18]  T. Chaudhuri,et al.  Role of C-reactive protein in schizophrenia: An overview , 2014, Psychiatry Research.

[19]  J. Salgado,et al.  Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review , 2014, Current neuropharmacology.

[20]  O. Cauli,et al.  Interleukin 6 and cognitive dysfunction , 2014, Metabolic Brain Disease.

[21]  Philip D. Harvey,et al.  Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension , 2013, European Neuropsychopharmacology.

[22]  Francisco Gude,et al.  Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study , 2013, BMC Endocrine Disorders.

[23]  S. Potkin,et al.  Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial , 2013, Schizophrenia Research.

[24]  A Sicras-Mainar,et al.  C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice , 2013, European Psychiatry.

[25]  F. Dickerson,et al.  C-reactive protein is elevated in schizophrenia , 2013, Schizophrenia Research.

[26]  A. Convit,et al.  Impact of metabolic syndrome on cognition and brain: a selected review of the literature. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Nancy Brahm,et al.  Schizophrenia and the immune system: pathophysiology, prevention, and treatment. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[28]  F. Panza,et al.  Metabolic syndrome as a risk factor for neurological disorders , 2012, Cellular and Molecular Life Sciences.

[29]  C. Jonker,et al.  The role of lipoproteins and inflammation in cognitive decline: Do they interact? , 2012, Neurobiology of Aging.

[30]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[31]  Michael F. Green,et al.  Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. , 2011, The American journal of psychiatry.

[32]  K. Kuboki,et al.  Small, dense LDL and high-sensitivity C-reactive protein (hs-CRP) in metabolic syndrome with type 2 diabetes mellitus. , 2010, Journal of atherosclerosis and thrombosis.

[33]  B. Yankner,et al.  Neural mechanisms of ageing and cognitive decline , 2010, Nature.

[34]  U. Singh,et al.  Human C-reactive protein and the metabolic syndrome , 2009, Current opinion in lipidology.

[35]  Y. Arbel,et al.  Comparative analysis of Bayer wide‐range C‐reactive protein (wr‐CRP) and the Dade‐Behring high sensitivity C‐reactive protein (hs‐CRP) in patients with inflammatory bowel disease , 2008, Journal of digestive diseases.

[36]  Emmanuel Stip,et al.  Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review , 2008, Biological Psychiatry.

[37]  J. Newcomer.  Metabolic syndrome and mental illness. , 2007, The American journal of managed care.

[38]  D. Goff,et al.  Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia , 2007, Psychiatry Research.

[39]  F. Ferro,et al.  The Role of C-Reactive Protein in Mood Disorders , 2006, International journal of immunopathology and pharmacology.

[40]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[41]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[42]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[43]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[44]  B. Efron,et al.  Bootstrap confidence intervals , 1996 .

[45]  D. G. Logan,et al.  Schizophrenia, an immunologic disorder? , 1970, JAMA.

[46]  P. Guest.  Insulin Resistance in Schizophrenia. , 2019, Advances in experimental medicine and biology.

[47]  Philip D. Harvey.  Inflammation in Schizophrenia: What It Means and How to Treat It. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[48]  D. Jeste,et al.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[49]  B. Miller,et al.  C-reactive protein levels in schizophrenia: a review and meta-analysis. , 2014, Clinical schizophrenia & related psychoses.

[50]  D. F. Drake,et al.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.

[51]  Peifeng Hu,et al.  Inflammation and rate of cognitive change in high-functioning older adults. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[52]  A. Aljada,et al.  Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.

[53]  R. Heath,et al.  Schizophrenia as an Immunologic Disorder: II. Effects of Serum Protein Fractions on Brain Function , 1967 .